RASON promotes KRASG12C-driven tumor progression and immune evasion in non-small cell lung cancer
This study reveals RASON as a key oncogenic regulator of KRAS<sup>G12C</sup> signaling, driving lung tumorigenesis and progression, and identifies RASON as a promising therapeutic target for KRAS<sup>G12C</sup> mutant non-small cell lung cancer.
Authors
- Chao Yan (ORCID: https://orcid.org/0000-0002-6029-224X)
- Yaliang Zhang (ORCID: https://orcid.org/0000-0002-1352-0676)
- Rutian Li (ORCID: https://orcid.org/0000-0003-4800-6156)
- Kexin Xie
- Tongyan Liu (ORCID: https://orcid.org/0000-0001-5677-4513)
- Jianzhuang Wu
- Weiyi Zhang (ORCID: https://orcid.org/0000-0002-5431-4166)
- Yixuan Zhang (ORCID: https://orcid.org/0000-0002-8131-0064)
- Tao Xu (ORCID: https://orcid.org/0000-0003-1984-1689)
- Rong Yin (ORCID: https://orcid.org/0000-0002-9744-4251)
- Qi Sun (ORCID: https://orcid.org/0000-0001-8276-0027)
- Rongjie Cheng
- Yudong Qiu (ORCID: https://orcid.org/0009-0007-8227-9322)
- Yugui Xia
Institutions
- Institute of Cancer Research (GB)
- Anhui Medical University (CN)
- Breast Cancer Now (GB)
- Nanjing Drum Tower Hospital (CN)
- Jiangsu Cancer Hospital (CN)
- Nanjing Medical University (CN)
- Nanjing University (CN)
Publication Details
- Journal
- Journal of Experimental & Clinical Cancer Research
- Published
- 2025-03-25
- DOI
- https://doi.org/10.1186/s13046-025-03369-9
- Citations
- 7
- Primary Topic
- Monoclonal and Polyclonal Antibodies Research
- Type
- article
- Field-Weighted Citation Impact
- 9.52
Funders
- National Natural Science Foundation of China